Lineage Cell Therapeutics Inc

Insider buying of Lineage Cell Therapeutics shows CEO confidence and a $60 million AT‑M raise, hinting at a bullish outlook for this mid‑cap biotech.

Lineage Cell Therapeutics’ latest insider activity shows CEO Brian Culley and senior execs aligning long‑term incentives with shareholder value as the company pushes cell‑therapy milestones, tackles regulatory & reimbursement hurdles, and leverages …